Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Conference News ACC 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

Shelley Wood

March 27, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

Perioperative Beta-blockade for Noncardiac Surgery Increases Death, Stroke at 1 Year

Yael L. Maxwell

March 15, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

Presentation ACC 2018

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Presenter: Tracy Wang

March 12, 2018

Presentation ACC 2018

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Presenter: Philip Devereaux

March 12, 2018

Presentation ACC 2018

One-year Clinical Outcomes of the Bio-engineered COMBO stent: Primary Results from the 3614 All-comer Patients in the COMBO Collaboration

Presenter: Antonio Colombo

March 11, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

Presentation ACC 2018

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Presenter: Francesco Franchi

March 11, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Conference News ACC 2018

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

Advertisement

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Perioperative Beta-blockade for Noncardiac Surgery Increases Death, Stroke at 1 Year

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

One-year Clinical Outcomes of the Bio-engineered COMBO stent: Primary Results from the 3614 All-comer Patients in the COMBO Collaboration

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content